- Report
- August 2025
- 188 Pages
Global
From €3133EUR$3,545USD£2,718GBP
€3481EUR$3,939USD£3,020GBP
- Report
- April 2025
- 200 Pages
Global
From €3968EUR$4,490USD£3,442GBP
- Report
- September 2025
- 485 Pages
Global
From €5170EUR$5,850USD£4,485GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2465EUR$2,789USD£2,138GBP
- Report
- August 2024
- 90 Pages
Global
From €5258EUR$5,950USD£4,562GBP
- Report
- May 2024
- 130 Pages
Global
From €5743EUR$6,499USD£4,982GBP
- Report
- October 2023
- 146 Pages
Global
From €3117EUR$3,528USD£2,704GBP
€3667EUR$4,150USD£3,182GBP
- Report
- April 2024
- 74 Pages
Global
From €3500EUR$4,243USD£3,143GBP
- Report
- November 2021
- 747 Pages
Global
From €3535EUR$4,000USD£3,067GBP
The Carcinoembryonic Antigen (CEA) market is a subset of the drug discovery industry. CEA is a biomarker used to detect and monitor certain types of cancer. It is used to diagnose and monitor the progression of colorectal, pancreatic, and other gastrointestinal cancers. CEA is also used to monitor the effectiveness of cancer treatments.
CEA-based drug discovery is a rapidly growing field, with many companies developing new treatments and diagnostic tools. Companies are developing CEA-based drugs to target specific cancer types, as well as to improve the accuracy of cancer diagnosis. Additionally, companies are developing CEA-based diagnostics to detect cancer earlier and more accurately.
Some companies in the CEA market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
